Trial Profile
Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Maraviroc (Primary) ; Ritonavir (Primary) ; Tenofovir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms VIRECURE
- 11 Mar 2020 Results analysing immunological changes in cell subsets in blood and rectal tissue as well as mucosal cytokine profile after initiating an intensified-5-drug ART regimen during very early PHI presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 05 Dec 2019 Status changed from recruiting to completed.
- 16 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Nov 2018.